Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 3
1997 12
1998 11
1999 42
2000 30
2001 32
2002 52
2003 51
2004 55
2005 58
2006 69
2007 45
2008 44
2009 60
2010 42
2011 53
2012 46
2013 44
2014 51
2015 47
2016 45
2017 45
2018 36
2019 43
2020 57
2021 35
2022 47
2023 46
2024 58
2025 47
2026 38

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,226 results

Results by year

Filters applied: . Clear all
Page 1
Fexofenadine.
Markham A, Wagstaff AJ. Markham A, et al. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. doi: 10.2165/00003495-199855020-00012. Drugs. 1998. PMID: 9506246 Review.
In a double-blind clinical trial, oral fexofenadine 120 or 180mg once daily controlled symptoms in patients with seasonal allergic rhinitis as effectively as cetirizine. Other double-blind clinical trials showed that fexofenadine 40 to 240mg twice daily was signific …
In a double-blind clinical trial, oral fexofenadine 120 or 180mg once daily controlled symptoms in patients with seasonal allergic rh …
Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.
Ansotegui IJ, Bousquet J, Canonica GW, Demoly P, Gómez RM, Meltzer EO, Murrieta-Aguttes M, Naclerio RM, Rosario Filho N, Scadding GK. Ansotegui IJ, et al. Curr Med Res Opin. 2024 Aug;40(8):1297-1309. doi: 10.1080/03007995.2024.2378172. Epub 2024 Jul 19. Curr Med Res Opin. 2024. PMID: 39028636 Free article.
Results of brain H(1)-receptor occupancy (H(1)RO) obtained from PET showed no H(1)RO by fexofenadine, the receptor which is known to cause sedation of H(1) antihistamines. Most studies calculating PIR value as 0 showed fexofenadine to be a non-impairing oral antihis …
Results of brain H(1)-receptor occupancy (H(1)RO) obtained from PET showed no H(1)RO by fexofenadine, the receptor which is known to …
The systemic safety of fexofenadine HCl.
Mason J, Reynolds R, Rao N. Mason J, et al. Clin Exp Allergy. 1999 Jul;29 Suppl 3:163-70; discussion 171-3. doi: 10.1046/j.1365-2222.1999.0290s3163.x. Clin Exp Allergy. 1999. PMID: 10444232 Review.
Fexofenadine is a highly specific, H1-receptor antagonist with a safety profile similar to placebo. ...Fexofenadine is formulated and marketed as the hydrochloride salt. The recommended dose of fexofenadine HC1 is 120 mg daily for SAR (either as 120 mg once d …
Fexofenadine is a highly specific, H1-receptor antagonist with a safety profile similar to placebo. ...Fexofenadine is formula …
Safety of second generation antihistamines.
Philpot EE. Philpot EE. Allergy Asthma Proc. 2000 Jan-Feb;21(1):15-20. doi: 10.2500/108854100778249033. Allergy Asthma Proc. 2000. PMID: 10748947 Review.
Second-generation antihistamines are less likely to produce sedation. Loratadine, cetirizine, and fexofenadine are the most commonly prescribed second-generation antihistamines. Many tests have been conducted to assess the central effects of these three drugs. ...Loratadin …
Second-generation antihistamines are less likely to produce sedation. Loratadine, cetirizine, and fexofenadine are the most commonly …
QT interval prolongation and beyond.
Couderc JP. Couderc JP. Ann Noninvasive Electrocardiol. 2006 Oct;11(4):287-8. doi: 10.1111/j.1542-474X.2006.00119.x. Ann Noninvasive Electrocardiol. 2006. PMID: 17040275 Free PMC article. No abstract available.
Clinical pharmacokinetics of fexofenadine enantiomers.
Miura M, Uno T. Miura M, et al. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Expert Opin Drug Metab Toxicol. 2010. PMID: 19947891 Review.
This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers. ...T …
This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports t …
Cardiovascular safety of fexofenadine HCl.
Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Pratt CM, et al. Am J Cardiol. 1999 May 15;83(10):1451-4. doi: 10.1016/s0002-9149(99)00124-1. Am J Cardiol. 1999. PMID: 10335761 Review.
Outliers were defined as QTc > 440 ms with a > or = 10 ms increase from baseline. The recommended fexofenadine HCl dose is 60 mg twice daily. Fexofenadine HCl doses up to 800 mg once daily or 690 mg twice daily for 28 days resulted in no dose-related increases …
Outliers were defined as QTc > 440 ms with a > or = 10 ms increase from baseline. The recommended fexofenadine HCl dose is 60 m …
Fexofenadine in pediatrics: oral tablet and suspension formulations.
Mansfield LE. Mansfield LE. Expert Opin Pharmacother. 2008 Feb;9(2):329-37. doi: 10.1517/14656566.9.2.329. Expert Opin Pharmacother. 2008. PMID: 18201155 Review.
The tablet formulation of the second-generation antihistamine fexofenadine has established efficacy and safety in both adults and children. To aid administration in young children, a new oral suspension formulation of fexofenadine has been developed, indicated for t …
The tablet formulation of the second-generation antihistamine fexofenadine has established efficacy and safety in both adults and chi …
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Devillier P, Roche N, Faisy C. Devillier P, et al. Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001. Clin Pharmacokinet. 2008. PMID: 18336052 Review.
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levocetirizine - many pharmacological and clinical criteria must be considered. ...Desloratadine and fexofenadine do not impair cognitive …
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levo …
Multiple H1-antihistamine-induced urticaria.
Inomata N, Tatewaki S, Ikezawa Z. Inomata N, et al. J Dermatol. 2009 Apr;36(4):224-7. doi: 10.1111/j.1346-8138.2009.00627.x. J Dermatol. 2009. PMID: 19348661
The patient consented to a provocation test of fexofenadine among drugs including cetirizine and hydroxyzine, which were suspected of inducing severe symptoms in episodes. ...Among the causative drugs in our case, cetirizine and hydroxyzine are the piperazine derivatives, …
The patient consented to a provocation test of fexofenadine among drugs including cetirizine and hydroxyzine, which were suspected of …
1,226 results